Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-26
2006-12-26
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S253000
Reexamination Certificate
active
07153861
ABSTRACT:
Pyrimidone compounds of formula (I):are inhibitors of the enzyme Lp-PLA2and are of use is treating atheroscelerosis.
REFERENCES:
patent: WO 99/24420 (1999-05-01), None
patent: WO 00/66567 (2000-11-01), None
Lerman, Women and Ischemia Syndrome Evaluation (WISE) Diagnosis and Pathophysiology of Ischemic Heart Disease Workshop, Oct. 2002.
Koren, Diastolic Congestive Heart Failure, Jacksonville Medicine, Feb. 2002.
Iribarren et al., Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Calcified Coronary Plaque in Young Adults, Arterioscler Thromb Vasc Biol., 25: 216-221, Jan. 2005.
McAllister et al., Randomised trials of secondary prevention programmes in coronary heart disease: systematic reveiw, BMJ, vol. 323, pp. 957-962, Oct. 2001.
Hickey et Chemical Abstracts vol. 135, Entry 195570 (2001).
Leach Colin Andrew
Smith Stephen Allan
Stanway Steven James
Kanagy James M.
Kinzig Charles
Rao Deepak
SmithKline Beecham p.l.c.
LandOfFree
5,6 -Trimethylenepyrimidin-4-one compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5,6 -Trimethylenepyrimidin-4-one compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5,6 -Trimethylenepyrimidin-4-one compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3715706